What does the data show about Ipca Laboratories Ltd. (IPCALAB)? Here's a rundown of its financials, valuation, and ownership picture.
Ipca Laboratories Revenue Trend
Ipca Laboratories Ltd. closed FY2026 with revenue of ₹9,646 Cr, up 7.9% from the ₹8,940 Cr it posted in FY2025.
Over the past 10 years, the company has compounded revenue at a 12.8% CAGR, solid growth by most standards. The top line climbed from ₹2,885 Cr to ₹9,646 Cr in that span.
At ₹9,646 Cr in annual revenue, Ipca Laboratories Ltd. sits in the mid-sized bracket among pharmaceuticals companies.
Ipca Laboratories Ltd. has now posted 10 straight years of revenue growth, a streak that stands out.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹9,646 Cr | +7.9% |
| FY2025 | ₹8,940 Cr | +16.0% |
| FY2024 | ₹7,705 Cr | +23.4% |
| FY2023 | ₹6,244 Cr | +7.1% |
| FY2022 | ₹5,830 Cr | — |
View Ipca Laboratories Ltd.'s full 10-year revenue trend with CAGR analysis →
Ipca Laboratories Profitability
Profitability held up well too: net income rose 50.8% to ₹1,184 Cr from ₹785 Cr a year earlier.
Margins improved as well, with net profit margin climbing to 12.3% from 8.8%.
Diluted EPS rose to ₹44.98 in FY2026, up from ₹29.08 in FY2025.
Is Ipca Laboratories Undervalued
Shares of Ipca Laboratories Ltd. currently trade at ₹1,725.60.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Ipca Laboratories Shareholding Pattern
Promoter holding has held steady at 44.7% across the past 4 quarters, a signal of confidence in where the company is headed.
Foreign institutional holding stands at 10.7% as of June 2026, up from 10.4%.
Domestic institutional holding, meanwhile, is at 37.4% as of June 2026, up from 36.8%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 44.7% | 10.7% | 37.4% | 7.2% |
| Mar 2026 | 44.7% | 10.6% | 37.5% | 7.2% |
| Dec 2025 | 44.7% | 10.6% | 37.3% | 7.3% |
| Sep 2025 | 44.7% | 10.4% | 36.8% | 8.1% |
Track quarterly shareholding changes for Ipca Laboratories Ltd. →
Ipca Laboratories Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹117.61B at the end of FY2025, up 5.9% from ₹111.01B a year earlier.
Property, Plant & Equipment is the largest block at 38.0%, followed by Inventories at 21.8% and Receivables at 15.9%.
Equity makes up 71.3% of liabilities and equity, with debt at 11.6% and operating liabilities at 17.1%. Over the year, debt is down 5.3% and equity is up 8.6%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 9.31B |
| Receivables | 18.74B |
| Inventories | 25.60B |
| Property, Plant & Equipment | 44.67B |
| Investments | 2.16B |
| Intangibles & Goodwill | 2.03B |
| Other Assets | 15.10B |
| Category | Value |
|---|---|
| Equity | 83.88B |
| Short-term Debt | 7.69B |
| Long-term Debt | 5.94B |
| Trade Payables | 8.46B |
| Other Liabilities | 11.63B |
Ipca Laboratories Investment Snapshot
Putting it all together, here's the picture for Ipca Laboratories Ltd. (IPCALAB) heading into the next fiscal year.
FY2026 revenue came in at ₹9,646 Cr, up 7.9% year-over-year.
Revenue has compounded at 12.8% annually over the past 10 years.
Profitability is solid, with a 12.3% net margin and net income of ₹1,184 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Ipca Laboratories Ltd..